Physician profile
Gary Miller
NPI 1558488197
$2,144.50
in general payments reported to CMS, 2019-2025
36 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.04 · 2020: $40.07 · 2022: $1,222 · 2023: $667 · 2024: $84.33 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $518.73 | 2022-2025 | |
| Emd Serono, INC. | $219.34 | 2022-2023 | Mavenclad |
| Biohaven Pharmaceutical Holding Company LTD. | $163.13 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $129.12 | 2020-2023 | Austedo, Austedo Xr |
| Acadia Pharmaceuticals INC | $100.47 | 2022-2023 | Nuplazid |
| Lundbeck LLC | $96.39 | 2024-2025 | Vyepti |
| Pfizer INC. | $77.35 | 2023 | |
| Biogen, INC. | $73.53 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $66.51 | 2023 | |
| Mdd US Operations, LLC | $53.21 | 2022-2023 | Xadago, Myobloc, Apokyn |
| Avion Pharmaceuticals | $49.07 | 2022-2023 | Dhivy |
| Argenx US, INC. | $46.37 | 2022-2023 | Vyvgart |
| Edwards Lifesciences Corporation | $41.97 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Genzyme Corporation | $37.02 | 2022 | |
| Upsher-Smith Laboratories LLC | $36.59 | 2022-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $35.80 | 2022 | |
| Sunovion Pharmaceuticals INC. | $32.68 | 2019-2022 | |
| Ucb, INC. | $31.10 | 2022 | |
| Grifols USA, LLC | $29.53 | 2022 | |
| Neurocrine Biosciences, INC. | $24.23 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.03 | 2022 | |
| Acorda Therapeutics, INC | $23.25 | 2022 | |
| Horizon Therapeutics Plc | $22.70 | 2022 | |
| Sk Life Science, INC. | $21.75 | 2023 | |
| Sumitomo Pharma America, INC. | $20.61 | 2023-2024 | Gemtesa, Aptiom |
| Scilex Pharmaceuticals INC. | $18.06 | 2022 | |
| Novo Nordisk INC | $18.00 | 2023 | Wegovy |
| Eisai INC. | $17.97 | 2023 | |
| Lilly USA, LLC | $17.07 | 2022 | |
| Genentech USA, INC. | $16.85 | 2022 | |
| Seqirus USA INC | $15.15 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.89 | 2023 | Ultomiris |
| Amneal Pharmaceuticals LLC | $13.40 | 2023 | Rytary |
| Astrazeneca Pharmaceuticals LP | $13.17 | 2024 | Farxiga |
| Amgen INC. | $12.84 | 2023 | Aimovig |
| Idorsia Pharmaceuticals US INC | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.